Suppr超能文献

不同他汀类药物对内皮细胞中内皮型一氧化氮合酶和AKT磷酸化的影响。

Effects of different statins on endothelial nitric oxide synthase and AKT phosphorylation in endothelial cells.

作者信息

Wang Juyong, Xu Zhenye, Kitajima Isao, Wang Zhongqi

机构信息

Tumor Institute of Traditional Chinese Medicine, Longhua Hospital; Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.

出版信息

Int J Cardiol. 2008 Jun 23;127(1):33-9. doi: 10.1016/j.ijcard.2007.10.034. Epub 2008 Jan 16.

Abstract

BACKGROUND

In the present study, we examined effects of pitavastatin and cerivastatin on NO production and their mechanisms in EC.

METHODS

HUVEC cells (1x10(4) cells/well) were seeded into 96-well plates in 100 microl of culture medium for overnight, and then treated with various concentrations of pitavastatin or cerivastatin for 48 h. The cytotoxicity was evaluated using a WST-8 assay; The cells were cultured for 6 h in 200 microl of fresh medium containing increasing doses of pitavastatin or cerivastatin at 37 degrees C for 6 h, the NO production was detected by diaminofluoresceins (DAFs) assay; Simultaneously, The cells (1 x 10(5) cells/well) were seeded into 96-well plates in medium for overnight, and then treated with reagents at 37 degrees C for 30 min, cGMP level was measured by enzyme-immunoassay. The cells were cultured in 2 ml of fresh medium containing increasing doses of pitavastatin or cerivastatin at 37 degrees C for 30 min, the phosphorylations of eNOS and Akt were detected by Western blotting.

RESULTS

We found that pitavastatin not only induced NO production, but also increased cGMP level in HUVECs. Furthermore, EC were incubated with pitavastatin or cerivastatin for 30 min, Western blot analysis showed that pitavastatin (0.1 microM) significantly upregulated the phosphorylation of eNOS and Akt about 1.4-fold or 1.3-fold compared with control, however, cerivastatin (0.1 microM) did not have any effects on them.

CONCLUSION

Low dose of pitavastatin (0.1 microM) involves Akt pathway, activates eNOS activity, increases cGMP level and produces NO in EC, which is higher than that of cerivastatin.

摘要

背景

在本研究中,我们检测了匹伐他汀和西立伐他汀对内皮细胞中一氧化氮(NO)生成的影响及其机制。

方法

将人脐静脉内皮细胞(HUVEC细胞,1×10⁴个细胞/孔)接种于96孔板中,加入100微升培养基培养过夜,然后用不同浓度的匹伐他汀或西立伐他汀处理48小时。使用WST - 8法评估细胞毒性;将细胞在含有递增剂量匹伐他汀或西立伐他汀的200微升新鲜培养基中于37℃培养6小时,通过二氨基荧光素(DAFs)法检测NO生成;同时,将细胞(1×10⁵个细胞/孔)接种于96孔板中,在培养基中培养过夜,然后于37℃用试剂处理30分钟,通过酶免疫测定法测量环磷酸鸟苷(cGMP)水平。将细胞在含有递增剂量匹伐他汀或西立伐他汀的2毫升新鲜培养基中于37℃培养30分钟,通过蛋白质印迹法检测内皮型一氧化氮合酶(eNOS)和蛋白激酶B(Akt)的磷酸化。

结果

我们发现匹伐他汀不仅能诱导HUVEC细胞生成NO,还能提高其cGMP水平。此外,将内皮细胞与匹伐他汀或西立伐他汀孵育30分钟,蛋白质印迹分析显示,与对照组相比,匹伐他汀(0.1微摩尔/升)能使eNOS和Akt的磷酸化显著上调约1.4倍或1.3倍,然而,西立伐他汀(0.1微摩尔/升)对它们没有任何影响。

结论

低剂量的匹伐他汀(0.1微摩尔/升)通过Akt途径,激活eNOS活性,提高cGMP水平,并在内皮细胞中产生NO,其作用强于西立伐他汀。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验